Immune Checkpoint Inhibitor Toxicities. (Record no. 29868733)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01137 a2200313 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518050058.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202001s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1942-5546 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/j.mayocp.2019.03.012 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Marin-Acevedo, Julian A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20200109 |
| 245 00 - TITLE STATEMENT | |
| Title | Immune Checkpoint Inhibitor Toxicities. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Mayo Clinic proceedings |
| Date of publication, distribution, etc. | 07 2019 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1321-1329 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Review |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents, Immunological |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Colonic Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunotherapy |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Ipilimumab |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Melanoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Programmed Cell Death 1 Receptor |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Skin Neoplasms |
| General subdivision | drug therapy |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chirila, Razvan M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dronca, Roxana S |
| 773 0# - HOST ITEM ENTRY | |
| Title | Mayo Clinic proceedings |
| Related parts | vol. 94 |
| -- | no. 7 |
| -- | p. 1321-1329 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/j.mayocp.2019.03.012">https://doi.org/10.1016/j.mayocp.2019.03.012</a> |
| Public note | Available from publisher's website |
No items available.